Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node Mapping in Patients With Endometrial Cancer

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorBarretos Cancer Hospital

About this trial

This Clinical trial will compare ICG cervical superficial injections versus superficial and deep injection for sentinel lymph node mapping in early-stage endometrial cancer patients

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women aged ≥18 years with a confirmed diagnosis of stage I endometrial cancer who underwent sentinel lymph node mapping with ICG at Barretos Cancer Hospital Treated using a minimally invasive approach (laparoscopic or robotic).

Disqualifiers

Allergic reaction of ICG and Iodo

Previous gynecologic oncology disease

Previous pelvic radiotherapy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Superficial cervical ICG injection

    Diagnostic test

    Superficial ICG cervical injections

  • Deep and superficial ICG cervical injection

    Diagnostic test

    Deep and superficial ICG cervical injection for sentinel lymph node mapping

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Superficial cervical ICG injectionExperimental treatment 1 intervention
Group B: Deep and superficial ICG cervical injectionActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Rate of pelvic bilateral sentinel lymph detection with superficial ICG cervical injection compared to deep and superficial cervical injection

Our primary objective will be to compare the bilateral pelvic sentinel lymph node detection rates between superficial cervical injection of ICG and combined deep and superficial cervical injection.

Time frame
12 weeks
2

Noninferiority of superficial ICG cervical injection for sentinel lymph node detection

The noninferiority of superficial cervical ICG injection compared with combined deep and superficial cervical injection for sentinel lymph node detection will be evaluated.

Time frame
From enrollment to the end of treatment at 12 weeks

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: